Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C
Hepatology, 05/25/2012Falleti F et al.
in difficult to treat hepatitis C virus (HCV) genotypes, simultaneous pre treatment normal serum vitamin D levels and the carriage of binding protein (GC)–globulin wild type isoform strongly predicts the achievement of sustained viral response (SVR) after PEG–interferon plus ribavirin antiviral therapy.
Two hundred six HCV patients treated with a combination therapy of PEG–interferon plus ribavirin were retrospectively evaluated.
GC rs7041 G>T, GC rs4588 C>A and IL–28B rs12979860 C>T polymorphisms were genotyped.
Frequencies of GC rs7041 G>T and rs4588 C>A polymorphisms were: G/G=64 (31.1%), G/T=100 (48.5%), T/T=42 (20.4%) and C/C=108 (52.4%), C/A=84 (40.8%), A/A=14 (6.8%).
Patients were divided into those carrying ≥3 major alleles (WT+: G–C/G–C, G–C/T–C, G–C/G–A, N=100) and the remaining (WT–: G–C/T–A, T–A/T–C, T–A/T–A, T–C/T–C, N=106).
Four groups were identified: vitamin D≤20 ng/mL and WT–, vitamin D≤20 and WT+, vitamin D>20 and WT–, vitamin D>20 and WT+.
In difficult to treat HCV genotypes the proportion of patients achieving SVR significantly increased with a linear trend from the first to the last group: 6/25 (24.0%), 9/24 (37.5%), 12/29 (41.4%), 19/29 (65.5%) (p=0.003).
At multivariate analysis having basal vitamin D >20 ng/mL plus the carriage of GC WT+ was found to be an independent predictor of SVR (O.R. 4.52, p=0.015).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.